TG Therapeutics Reports $161.7 Million Revenue in Latest Quarter, Driven by BRIUMVI Sales

TG Therapeutics, Inc. reported significant financial growth in its latest quarterly filing, with total revenue reaching $161.7 million for the three months ended September 30, 2025, compared to $83.9 million for the same period in 2024. This increase was primarily driven by product revenue from BRIUMVI, which amounted to $159.3 million, up from $83.3 million year-over-year. For the nine months ending September 30, 2025, total revenue was $423.7 million, a substantial rise from $220.8 million in the prior year. The company achieved a net income of $390.9 million for the third quarter, a significant increase from $3.9 million in the same quarter last year, largely due to a substantial income tax benefit resulting from the release of a deferred tax asset valuation allowance.

The company’s operational metrics also showed notable changes. The cost of revenue increased to $28.1 million for the third quarter of 2025, compared to $9.3 million in the previous year, reflecting higher royalties and manufacturing costs associated with BRIUMVI sales. Research and development expenses rose to $40.9 million, up from $20.1 million, driven by increased clinical trial costs and manufacturing expenses related to the development of subcutaneous ublituximab. Selling, general, and administrative expenses also increased to $63.4 million from $42.0 million, attributed to higher marketing and personnel costs as the company expands its commercialization efforts.

Strategically, TG Therapeutics has made significant advancements, including the completion of a $100 million share repurchase program in September 2025, which involved repurchasing 3.5 million shares at an average price of $28.55. The company has also initiated a new share repurchase program for an additional $100 million. Furthermore, TG Therapeutics continues to expand its product offerings, with BRIUMVI now approved in multiple international markets, including the European Union, the United Kingdom, and Australia. The company is also advancing its clinical pipeline, with ongoing trials for subcutaneous ublituximab and azer-cel, a CAR T therapy for autoimmune diseases.

As of September 30, 2025, TG Therapeutics reported total assets of $1.025 billion, with cash and cash equivalents amounting to $74.1 million. The company’s accumulated deficit stood at approximately $1.1 billion, reflecting its historical operating losses. Despite recent profitability, the company acknowledges the need for substantial revenue generation to sustain long-term profitability and positive cash flow. Looking ahead, TG Therapeutics anticipates that its current cash reserves, along with projected revenues, will be sufficient to meet its liquidity needs for at least the next twelve months, although it may require additional financing to support ongoing operations and product development.